Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16859833 | 0.81 | MAPK14 (0.64) | JAK2KITMAPK14MAPK13MAPK12 | |
| SCHEMBL1011086 | 0.79 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL21436398 | 0.78 | MAPK14 (0.51) | JAK2KITMAPK14MAPK13MAPK12 | |
| SCHEMBL1599883 | 0.78 | MAPK14 (0.62) | JAK2KITMAPK14MAPK13MAPK12 | |
| SCHEMBL16537342 | 0.77 | KIT (1.00) | JAK2KITNTRK1HPGDGAA | |
| SCHEMBL1012719 | 0.77 | MAPK13 (0.78) | JAK2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600606 | 0.77 | MAPK14 (0.66) | JAK2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1599957 | 0.77 | JAK2 (0.71) | JAK2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1599975 | 0.76 | CDK8 (0.58) | JAK2KITMAPK14MAPK13MAPK12 | |
| SCHEMBL1600918 | 0.76 | MAPK14 (0.68) | JAK2MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | JAK2 4166/4885KIT 4277/4885MAPK14 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.